De novo podocytopathy following moderna COVID-19 vaccine: A case report and racial disproportionality in adverse effect reports

Li-Yu Hong; Chii-Hong Lee; I-Jen Chiu

doi:10.3389/fmed.2022.844004

De novo podocytopathy following moderna COVID-19 vaccine: A case report and racial disproportionality in adverse effect reports

Front Med (Lausanne). 2022 Aug 16:9:844004. doi: 10.3389/fmed.2022.844004. eCollection 2022.

Authors

Li-Yu Hong^{1

2

3}, Chii-Hong Lee⁴, I-Jen Chiu^{1

2

3}

Affiliations

¹ Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
² Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
³ TMU-Research Center of Urology and Kidney, Taipei Medical University, Taipei, Taiwan.
⁴ Department of Anatomical Pathology, Taipei Institute of Pathology, Taipei, Taiwan.

Abstract

In this study, we report a case of de novo minimal change disease shortly after the second dose of the Moderna COVID-19 vaccine. A previously healthy 51-year-old Asian man presented with lower-limb edema and foamy urine 3 days after receiving the second dose of the vaccine. Laboratory data revealed the following: serum creatinine, 0.65 mg/dl; serum albumin, 1.3 g/dl; urine protein-to-creatinine ratio, 15.3 g. A renal biopsy was performed, and minimal change in the disease was confirmed. The patient achieved complete remission in the tenth week after starting treatment with prednisolone (1 mg/kg/day). Ethnic differences may influence the adverse effects of drugs and vaccines. However, there is very limited data to address the influence of ethnic diversity on disease prevalence, clinical presentation, and treatment outcomes in COVID-19 vaccine-associated glomerulonephritis.

Keywords: COVID-19 vaccination; adverse (side) effects; disproporionality; minimal change disease; race.

Publication types

Case Reports